Exploiting for Breast Cancer Control a Proposed Unified Mechanism for Reduction of Human Breast Cancer Risk by the Hormones of Pregnancy

2007 ◽  
Author(s):  
Herbert Jacobson ◽  
Thomas T. Andersen ◽  
James A. Bennett
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Human Breast Cancer ◽  
Cancer Control ◽  
Human Breast ◽  
Breast Cancer Control

scholarly journals Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk

2008 ◽  
Vol 29 (11) ◽  
pp. 2132-2138 ◽  
Author(s):  
Tasha R. Smith ◽  
Edward A. Levine ◽  
Rita I. Freimanis ◽  
Steven A. Akman ◽  
Glenn O. Allen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Repair ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Genetic Polymorphisms ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Polygenic Model

Comparison of the Effect of Progesterone, Medroxyprogesterone Acetate and Norethisterone on the Proliferation of Human Breast Cancer Cells

2003 ◽  
Vol 9 (1) ◽  
pp. 36-38
Author(s):  
Harald Seeger ◽  
Diethelm Wallwiener ◽  
Alfred O Mueck
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Medroxyprogesterone Acetate ◽  
Human Breast Cancer ◽  
Chemosensitivity Test ◽  
Human Breast ◽  
Long Term Treatment

Objective To investigate in vitro the influence of the three most used progestogens in continuous combined HRT on cell proliferation of the human breast cancer cell line MCF-7. Study design Progesterone (P), medroxyprogesterone acetate (MPA) and norethisterone (NET) were investigated in the range of 0.01 nM to 10 μM alone and in combination with 10 nM oestradiol. Cell proliferation was measured after seven days using the ATP-chemosensitivity test. Results P alone reduced cell proliferation by 20 and 40% at 10−7 and 10−5 M. MPA and NET displayed a significant inhibition of cell proliferation between 20 and 25% for MPA and 23 and 41% for NET over the whole concentration range tested. The effect was greatest at 10−7 M for MPA and at 10−9 M for NET. In combination with oestradiol, P still significantly reduced cell proliferation, the values being between 12 and 61%. For MPA too an inhibitory effect between 20 and 40% was found, whereas for NET the values were between 23 and 38%. Conclusions Our in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women may depend on the type of progestogen used as well as on the regimen applied. However, the inhibitory in vitro net effect of the progestogens at clinically relevant dosages is rather minimal and it remains uncertain as to whether progestogens generally may reduce breast cancer risk in long-term treatment. Further clinical trials are urgently required to determine the appropriate choice - if any - of progestogen to complement HRT.

A Proposed Unified Mechanism for the Reduction of Human Breast Cancer Risk by the Hormones of Pregnancy

2009 ◽  
Vol 3 (2) ◽  
pp. 212-220 ◽  
Author(s):  
Herbert I. Jacobson ◽  
Nicole Lemanski ◽  
Anu Agarwal ◽  
Amithi Narendran ◽  
Kelvin E. Turner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Human Breast Cancer ◽  
Human Breast

scholarly journals In-silico QTL mapping of postpubertal mammary ductal development in the mouse uncovers potential human breast cancer risk loci

2015 ◽  
Vol 26 (1-2) ◽  
pp. 57-79 ◽  
Author(s):  
Darryl L. Hadsell ◽  
Louise A. Hadsell ◽  
Walter Olea ◽  
Monique Rijnkels ◽  
Chad J. Creighton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Qtl Mapping ◽  
In Silico ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Ductal Development

Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention

2001 ◽  
Vol 3 (4) ◽  
pp. 314-321 ◽  
Author(s):  
Norman F. Boyd ◽  
Lisa J. Martin ◽  
Jennifer Stone ◽  
Cary Greenberg ◽  
Salomon Minkin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Mammographic Densities
Sign in / Sign up

Export Citation Format

Share Document